Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
8
×
fda
8
×
life sciences
national blog main
national top stories
novartis
8
×
boston top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
deals
ipo
medical devices
startups
abbvie
amgen
biogen
cancer
deerfield management
What
roundup
bio
fda
medicines
new
biofourmis
biotech
covid
days
deal
devices
drugs
help
including
ipo
news
abbvie’s
according
acquire
acquisitions
activity
agreed
ahead
akcea
analytics
announced
approvals
august
bails
billion
biogen
brand
bridgebio
brings
bucks
busy
cancer
capital
car
cases
Language
unset
8
×
Current search:
unset
×
novartis
×
fda
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More